Navigation Links
Cancer stem cell marker also drives transcription in normal cells
Date:1/17/2008

New research links the recently discovered function of a multi-faceted transcriptional complex to control of gene expression in both normal cells and cancer stem cells. Two separate studies, published by Cell Press in the January 18th issue of Molecular Cell, provide insight into novel subunits associated with an evolutionarily conserved transcriptional regulatory complex and reveal a previously undescribed chromatin function that is required for full activity of nuclear receptors in normal cells and for the MYC oncoprotein in tumor cells.

Initiation of transcription requires sophisticated coordination of many different regulatory factors. Coactivators are multi-subunit complexes that facilitate transcription initiation directly, by interacting with RNA polymerase and general transcription factors, or indirectly, by influencing chromatin. For example, histone acetyltransferase (HAT) complexes are thought to activate gene expression by modifying chromatin-associated proteins called histones which function like spools for DNA to wind around.

The yeast SAGA complex and the homologue metazoan TFTC/STAGA, also called hSAGA, are HAT-containing complexes that facilitate access of general transcriptional factors to DNA through histone acetylation. Although hSAGA is thought to be a homologue of the well-studied yeast SAGA complex, its subunit composition and functions are not as well understood. Dr. Didier Devys from the Institute de Gntique et de Biologie Molculaire et Cellulaire in Strasbourg, France and colleagues identified three novel subunits, ATXN7L3, USP22 and ENY2, that are homologues of previously described subunits in the yeast SAGA complex.

The researchers demonstrated that the newly identified subunits work together to remove the ubiquitin moiety from monoubiquitylated histone H2B, similarly to what has been previously described in yeast, but also remove the ubiquitin moiety from monoubiquitylated histone H2A. The latter modification is not found in yeast but is more prevalent than monoubiquitylated H2B in mammals. Importantly, the deubiquitylation module of the Drosophila TFTC/STAGA complex was an enhancer of position effect variegation and counteracted heterochromatin silencing while both the Drosophila and the human deubiquitylation module were shown to be required for full transcriptional activation by the androgen receptor. This finding is clinically significant as androgen receptor activity is often deregulated in prostate cancer.

The association of both HAT and deubiquitylation activities in the hSAGA complex provide an attractive mechanism by which the so called cross-talk between given histone marks is coordinated within the same regulatory complex says Dr. Devys. Further mechanistic studies are essential to examine the exact link between these activities and other chromatin modifying complexes to understand how these sequential events participate in chromatin remodeling and gene activation.

Working in parallel, a second research group led by Dr. Steven B. McMahon from Thomas Jefferson Universitys Kimmel Cancer Center in Philadelphia also identified USP22 as a member of hSAGA. Previous work had identified USP22 as part of an eleven gene cancer stem cell signature that accurately distinguished patients whose tumors would eventually metastasize from those whose tumors would remain localized. Unlike the other genes in this cancer stem cell signature, no direct mechanistic link to human cancer has been ascribed to USP22, explains Dr. McMahon. McMahons group demonstrated that USP22 is required for activation of target gene transcription by the MYC oncoprotein and that USP22 depletion compromises MYC functions, including transformation of mammalian cells, and leads to cell cycle arrest.

Taken together, these results significantly advance the understanding of mechanisms that permit fine-tuning of transcriptional regulation by revealing that the hSAGA histone acetyltransferase complex is also capable of histone deubiquitylation. The findings provide critical new information about the importance of the timing and sequence of chromatin modifications in the control of gene expression in normal cells and shed light on the biochemical function of cancer stem cell marker and hSAGA subunit USP22, identifying it as a potential therapeutic target.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Just hours apart, 2 brothers undergo robotic prostate cancer surgery
2. Consuming extra virgin olive oil helps to combat degenerative diseases such as cancer
3. New gene test for prostate cancer at hand
4. Biological Link Between BRCA1 and Breast Cancer Detailed
5. Study finds that blood test can gauge prostate cancer risk
6. Gene markers located for hereditary prostate cancer
7. Genetic Mutations Boost Prostate Cancer Risk
8. Researchers Hone in on Cancer Stem Cells for Melanoma
9. HRT Raises Risk of Lobular Breast Cancer
10. Gastric cancer survivors should be aware of osteoporosis
11. Indian medicinal plant Acanthus ilicifolius may combat liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is ... KLS is a longtime supporter of the event. , "We are pleased that ... said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... community for those in the fight against cancer, has produced a seminal study ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... Our high-octane society ... even the sharpest brain. , Power On, a mental performance enhancer from Modus ... the brain. Each capsule contains Cognizin® Citicoline, a branded form of the brain ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , February 23, 2017 The fast-growing ... the United States . According to the 2017 ... industry is expected to create 283,422 jobs by 2020, with ... over the next four years. The accelerating pace of cannabis ... growth of legal cannabis market, which will further create more ...
(Date:2/23/2017)... 2017 The top three players ... Healthcare, Koninklijke Philips N.V., and Schiller. Collectively, these companies ... market in 2015. Strong product portfolio and a monumental ... be aiding these players remain leaders in the fragmented ... in the global market are likely to focus on ...
(Date:2/23/2017)... Feb. 23, 2017   SeraCare Life Sciences ... in vitro diagnostics manufacturers and clinical laboratories, is ... Implementation of NGS-Based Tests" to be hosted by ... at 11am Eastern Standard Time (US). ... the need for improved performance and global standardization ...
Breaking Medicine Technology: